Status:
UNKNOWN
Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
Lead Sponsor:
Yooyoung Pharmaceutical Co., Ltd.
Conditions:
Dyslipidemias
Eligibility:
MALE
19+ years
Phase:
PHASE1
Brief Summary
To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A
Detailed Description
Phase 1 to evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A. Which is designed as ramdomized, oral, single dose, two-way ...
Eligibility Criteria
Inclusion
- Over 19 ages healthy men
- Over 50.0kg, 18.0kg/m2 ≤ BMI ≤ 30.0kg/m2
- Men who don't have congenital disease and other cronic disease need to be cared. etc.
Exclusion
- Men who have congenital liver disease (AST, ALT, CK ≥ 2X ULN)
- Men who have drunken or eatten something including caffeine within 24 hours before. etc.
Key Trial Info
Start Date :
January 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04874129
Start Date
January 7 2021
End Date
July 31 2021
Last Update
May 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungbuk National Unviersity Hosipital
Cheongju-si, South Korea